Skip to content

RED-FLAGS Index Validation in Crohn's Disease Patients

Validation of the RED-FLAGS Index for Early Diagnosis of Crohn's Disease: Prospective Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02940054
Acronym
RED-FLAGS2
Enrollment
600
Registered
2016-10-20
Start date
2015-02-28
Completion date
2018-03-31
Last updated
2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease

Keywords

Early diagnosis

Brief summary

Observational prospective study to validate a new index for early diagnosis of Crohn's disease (CD)

Detailed description

The study will be conducted in Italian referral centers for Crohn's disease and will involve general practitioners (GPs) for RED-Flags Index validation. The project is divided into two phases. 1. retrospective phase (4 weeks). All the general practitioners participating to the study will extrapolate from their patient's database, the total number of patients with a Crohn's disease diagnosis performed in the past. The date of diagnosis will be indicated. No other information will be provided. These data will be then analyzed to obtain, for each GP, the total number of CD diagnosed in each semester. 2. retrospective phase (6 months). GPs will administer the RED-Flags questionnaire to all patients that meet inclusion and exclusion criteria, after informed consent signature. All these patients will be then referred to the nearest referral center, to be evaluated by a gastroenterologist specialized in CD, to confirm or exclude a CD.

Interventions

OTHERRed-flags questionnaire

A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.

Sponsors

Takeda
CollaboratorINDUSTRY
IG-IBD talian Group for Inflammatory Bowel Diseases
CollaboratorUNKNOWN
Istituto Clinico Humanitas
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. at least one of the following symptoms, for at least 4 weeks (either continuous or intermittent) 1. diarrhea (\>3 bowel movements per day) 2. nocturnal diarrhea 3. weight loss (≥5% of usual body weight) 4. abdominal pain (chronic or intermittent) 5. perianal lesions or fistulae or perianal abscess (hemorrhoidal diseases excluded) 2. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion criteria

1. known diagnosis of Crohn's disease, ulcerative colitis, chronic diverticulosis or any other gastrointestinal disease 2. any clinical condition that, in the opinion of the investigator, can alter stud results 3. inability to understanding and complying with protocol requirements 4. informed consent not signed and dated by the subject

Design outcomes

Primary

MeasureTime frameDescription
Sensibility of the Red Flags Indexat enrollmentSensibility, specificity, accuracy, positive and negative likelihood ratio measurement

Secondary

MeasureTime frameDescription
Cut-off for Crohn's disease diagnosisat enrollmentIdentification of the cut-off associated with an early diagnosis of Crohn's disease
Percentage of early diagnosed6 months of prospective periodPercentage of early diagnosed of Crohn's Disease in the 6 months of prospective use of the tool

Countries

Italy

Contacts

Primary ContactSilvio Danese, MD, PhD
IBDclinicaltrials@humanitas.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026